JMP Securities raised the firm’s price target on Aura Biosciences to $23 from $19 and keeps an Outperform rating on the shares. Aura presented final Phase 2 data for bel-sar that support success in Phase 3 and could provide a transformational option for patients with early-stage choroidal melanoma, the analyst tells investors in a research note. The update is meaningful given the small overall Phase 2 ‘n’ and it confirms Aura powered the ongoing Phase 3 CoMpass trial conservatively, the firm says.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AURA:
- 3 Best Stocks to Buy Now, 9/13/2024, According to Top Analysts
- Aura Biosciences’ Breakthrough in Choroidal Melanoma Treatment
- Aura Bioscience’s bel-sar shows positive Phase 2 results in melanoma study
- Aura Biosciences Reports Positive Phase 2 End of Study Results Evaluating Bel-sar as a First-Line Treatment for Early-Stage Choroidal Melanoma
- Aura Biosciences initiated with an Outperform at LifeSci Capital